<DOC>
	<DOCNO>NCT00050830</DOCNO>
	<brief_summary>The purpose study determine activity CI 1033 tumor patient advance metastatic NSCLC fail prior platinum-based combination chemotherapy . Another objective determine safety CI 1033 .</brief_summary>
	<brief_title>A Phase 2 , Randomized , Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Canertinib dihydrochloride</mesh_term>
	<criteria>Histologically cytologically document diagnosis progressive recurrent , locally advanced metastatic NSCLC ; tumor express least one member erbB family receptor ; fail relapse receive platinumcontaining regimen therapy ; least one measurable target lesion define RECIST irradiate . Prior exposure agent target erbB receptor family ; unknown response prior platinumcontaining chemotherapy regimen ; cytotoxic chemotherapy within 3 week prior baseline disease assessment ( 6 week nitrosoureas mitomycin ) ; 2 prior chemotherapy regimen : immunotherapy biologic therapy within 2 week prior baseline disease assessment ; prior irradiation area encompass great 30 % marrowbearing bone ; brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>